Oncolys BioPharma, Inc. (JP:4588) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncolys BioPharma Inc. saw a significant decline in net sales, dropping 50.2% to 31 million yen for the first nine months of 2024 compared to the same period in 2023. Despite a challenging financial performance, the company improved its equity ratio to 81.5%, up from 71.5% at the end of 2023. Notably, the company did not provide a forecast for the fiscal year ending December 2024 due to uncertainties in making reasonable estimates.
For further insights into JP:4588 stock, check out TipRanks’ Stock Analysis page.